Project Grant R43MD021361
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $296K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Hanover, MD 21076, USA
Similar Awards
- Federal Grant Award Summary Darwin Biosciences, Inc. received a $399,998 Project Grant award dated July 17, 2025, from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an innovative point-of-need lung cancer screening device for low-resource settings. The company is adapting its existing handheld diagnostic platform—previously developed under a $12 million Department of Defense contract for pathogen detection—to identify lung cancer...
- Federal Grant Award Summary Cereus Diagnostics Corp. received a $764,448 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 1, 2025, with completion targeted for July 31, 2028. The company is developing LUNG-FAST (Fragment Analysis, SNP, and Translocations), a rapid polymerase chain reaction (PCR)-based diagnostic test designed to detect clinically actionable lung cancer mutations including EGFR, KRAS, ALK,...
- The National Science Foundation awarded Rumedical Nova LIMITED Liability Company $305,000 on July 15, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to design and validate a compact chip-based platform for detecting lung cancer biomarkers in blood serum with high sensitivity and speed. The research will focus on developing an innovative nanoscale sensing element capable of recognizing disease signals at extremely low concentrations in a rapid, sensitive, and...
- The National Cancer Institute awarded University of Connecticut Health Center $414,585 on May 6, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate a programmable enzyme-assisted mutation sequencing (PEAM-SEQ) diagnostic platform for detecting cell-free DNA mutations in blood samples to enable noninvasive, early detection of lung cancer. The project will advance a PCR-based PEAM-SEQ V1.0 assay into a simplified PEAM-SEQ V2.0 assay by combining...
- The National Cancer Institute awarded $1,057,841 to Pathware Inc. on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) as a Small Business Innovation Research Direct-to-Phase II grant (R44CA302204). Pathware is developing an automated imaging platform combining coded ptychography with artificial intelligence algorithms to evaluate the diagnostic adequacy of unstained lung biopsy samples at the point of care. The system provides rapid on-site evaluation...
- The National Institutes of Health National Cancer Institute awarded Pulmera, Inc., $1.131690 million on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop advanced three-dimensional imaging technology to improve diagnostic accuracy during bronchoscopic lung biopsy for suspected lung cancer. Bronchoscopic lung biopsy currently achieves diagnostic accuracy of 60–82%, substantially lower than transthoracic needle aspiration, which benefits from...
- Federal Cooperative Agreement Award Summary The National Cancer Institute (NCI) awarded a $525,013 Cooperative Agreement to The University of Texas MD Anderson Cancer Center, effective September 1, 2025 through August 31, 2030, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394). This award funds translational research to validate blood-based biomarkers for lung cancer risk assessment among individuals with no smoking history. The project will evaluate the predictive...
- The National Cancer Institute awarded Molecular Targeting Technologies, Inc. $637,529 on August 24, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop targeted radionuclide therapy for non-small cell lung cancer using Lu-177 EBRGD. The award funds research to evaluate in vivo tumor targeting, biodistribution, therapeutic efficacy, and normal tissue toxicity of 177Lu-DOTA-EB-RGD as a treatment for non-small cell lung cancer, which accounts for 80–85 percent...
- The National Cancer Institute awarded Senticell LLC $399,995 for a Phase I Small Business Technology Transfer (STTR) project grant on September 1, 2026, to develop an red blood cell–based liquid biopsy platform for detecting circulating tumor DNA in early-stage non-small cell lung cancer. The recipient will establish the biological and clinical performance of RBC-bound tumor DNA detection using vertebrate animal models of KRAS- and EGFR-driven lung cancer to characterize in vivo kinetics of...
- The Department of Health and Human Services National Institute for Minority Health and Health Disparities awarded Collective Good DX, Inc. $349,322 on August 9, 2026, under the Minority Health and Health Disparities Research program (CFDA 93.307) to develop a mobile peer-consult platform that leverages collective intelligence and adaptive machine learning to improve diagnostic accuracy in rural and underserved clinical settings. The platform will dynamically assess clinician expertise...